List of Excipients in Branded Drug KYNAMRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kastle Therapeutics LLC	KYNAMRO	mipomersen sodium	70688-0502	HYDROCHLORIC ACID	2027-01-29
Kastle Therapeutics LLC	KYNAMRO	mipomersen sodium	70688-0502	SODIUM HYDROXIDE	2027-01-29
Kastle Therapeutics LLC	KYNAMRO	mipomersen sodium	70688-0502	WATER	2027-01-29

KYNAMRO Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

KYNAMRO, the brand name for mipomersen sodium, was a once-weekly antisense oligonucleotide injection approved in the United States for homozygous familial hypercholesterolemia, or HoFH. Its commercial product used a simple aqueous formulation containing sodium chloride, pH-adjusting agents, and water for injection. The main commercial opportunity is not a conventional excipient reformulation of an active product. KYNAMRO’s U.S. approval was withdrawn after commercial discontinuation, so opportunities now center on product redevelopment, formulation licensing, manufacturing know-how, and alternative delivery systems.

What is KYNAMRO and why does its formulation matter?

KYNAMRO is a 2'-O-methoxyethyl antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA. The drug reduces hepatic production of apoB-containing lipoproteins, including LDL cholesterol and lipoprotein(a).

Product attribute	KYNAMRO
Active ingredient	Mipomersen sodium
Therapeutic class	Antisense oligonucleotide
Original sponsor	Ionis Pharmaceuticals
Commercial partner	Genzyme, later part of Sanofi
FDA approval	January 2013
Indication	Homozygous familial hypercholesterolemia
Dose	200 mg subcutaneously once weekly
Product presentation	200 mg in 2 mL prefilled syringe
Concentration	100 mg/mL
Original route	Subcutaneous
U.S. status	Commercially discontinued; approval withdrawn at sponsor request
Orphan-drug status	Yes

The product’s excipient system was deliberately limited. KYNAMRO used sodium chloride for tonicity, sodium hydroxide and hydrochloric acid for pH adjustment, and water for injection as the vehicle. The formulation was supplied as a sterile solution for subcutaneous injection, not as a lyophilized product requiring reconstitution.[1]

The formulation challenge is the high drug concentration. A 100 mg/mL antisense oligonucleotide solution must maintain chemical integrity, control aggregation, limit subcutaneous injection discomfort, and remain compatible with the prefilled syringe and container-closure system.

What excipients were used in KYNAMRO?

KYNAMRO’s labeled inactive ingredients were:

Excipient	Function in formulation
Sodium chloride	Tonicity adjustment
Sodium hydroxide	pH adjustment
Hydrochloric acid	pH adjustment
Water for injection	Solvent and injectable vehicle

The formulation did not rely on a complex stabilizer system containing sugars, amino acids, surfactants, or polyols. The sparse excipient profile reduced regulatory complexity and limited potential sources of immunogenicity or local irritation.

The commercial formulation was described as a clear, colorless to slightly yellow solution. The label identified a pH of approximately 7.5.[1]

What the KYNAMRO formulation excluded

The product did not use a visible particulate-forming suspension system. It also did not use:

• Polysorbate 20 or polysorbate 80
• Sucrose or trehalose
• Histidine buffer
• Citrate buffer
• Albumin
• Benzyl alcohol
• A preservative system for multidose administration

That design is consistent with a single-dose, prefilled injectable product. Avoiding surfactants and preservatives can simplify extractables and leachables work, reduce injection-site tolerability concerns, and narrow the analytical control strategy.

What formulation risks affect mipomersen and similar antisense drugs?

The principal formulation risks are chemical degradation, physical aggregation, adsorption, injection-site tolerability, and delivery-device compatibility.

Chemical stability

Antisense oligonucleotides can undergo degradation through pathways involving hydrolysis, oxidation, depurination, and modification of backbone or sugar substituents. Mipomersen’s phosphorothioate backbone and 2'-O-methoxyethyl chemistry improve biological durability but do not eliminate the need for tight control of pH, temperature, oxygen exposure, and trace metals.

A redevelopment program would normally evaluate:

• pH-dependent degradation
• Oxidative degradation
• Freeze-thaw stability
• Photostability
• Agitation sensitivity
• Hold-time stability during filling
• Compatibility with sterilizing filtration
• Container-closure adsorption
• Subvisible and visible particles

The original near-neutral pH is commercially useful because strongly acidic or alkaline conditions can increase local pain and accelerate certain degradation pathways.

Physical stability

At 100 mg/mL, the active concentration creates a risk of viscosity increase, self-association, and aggregation. These risks are relevant to syringeability and dose delivery. A formulation with a lower ionic strength may improve some stability attributes but can increase injection discomfort or alter molecular interactions.

Potential excipient screens could include:

• Sodium chloride concentration optimization
• Phosphate, histidine, or acetate buffers
• Sucrose or trehalose as stabilizers
• Arginine or other aggregation modifiers
• Low concentrations of nonionic surfactants
• Chelators for trace-metal control

Each candidate adds regulatory and manufacturing burden. For a subcutaneous oligonucleotide, excipient selection must be supported by local-tolerance data, not only by accelerated stability results.

Device compatibility

KYNAMRO was supplied in a prefilled syringe. A redevelopment program would need to evaluate:

• Silicone oil levels in the syringe
• Tungsten residues from syringe manufacture
• Elastomer extractables
• Needle gauge and injection force
• Protein- or oligonucleotide-like adsorption to contact surfaces
• Dose recovery at the end of shelf life
• Compatibility with autoinjector systems

The active is a synthetic oligonucleotide rather than a protein, but high-concentration nucleic-acid solutions can still interact with container surfaces and device components.

What commercial opportunities exist for KYNAMRO excipient redevelopment?

The strongest opportunity is a new product with improved tolerability or convenience, not a direct copy of the discontinued formulation.

Opportunity 1: Reintroducing mipomersen for an orphan population

HoFH is a severe inherited lipid disorder with a small addressable population. KYNAMRO’s original therapeutic proposition was weakened by liver-related safety concerns, including hepatic steatosis and transaminase elevations, as well as frequent injection-site reactions.[1]

A reintroduction strategy would require a differentiated clinical and commercial profile. Excipient changes alone are unlikely to overcome active-ingredient safety limitations. The commercial case would be stronger if formulation development were paired with:

• Lower injection volume
• Reduced injection-site pain
• Longer room-temperature stability
• Improved syringeability
• Autoinjector delivery
• Lower dosing frequency
• Improved hepatic safety through dose or exposure optimization

Opportunity 2: High-concentration subcutaneous delivery

A high-concentration formulation could support a smaller injection volume. KYNAMRO already used 100 mg/mL, so the value of further concentration increases would depend on viscosity, tolerability, and device performance.

The opportunity is strongest if a new formulation can maintain the 200 mg dose in a volume materially below 2 mL. That could improve patient acceptance and support an autoinjector or wearable injector.

Opportunity 3: Preservative-free multidose systems

A multidose presentation could reduce packaging and administration costs, but it would require a robust antimicrobial-control strategy. Preservatives could introduce local-tolerability and regulatory issues. A preservative-free multidose device with validated microbial protection could have commercial value, although the device and regulatory package would be more complex than the original single-dose syringe.

Opportunity 4: Alternative delivery technologies

The most valuable intellectual property may sit outside traditional excipients. Potential platforms include:

• Autoinjectors
• On-body delivery systems
• Microneedle arrays
• Depot formulations
• Lipid or polymer delivery systems
• Implantable or sustained-release systems
• Oral or targeted hepatic delivery platforms

For mipomersen, systemic exposure and hepatic uptake are central to activity. A delivery technology that improves liver targeting while reducing peripheral exposure could have greater value than a conventional buffer change.

What regulatory exclusivity applied to KYNAMRO?

KYNAMRO received orphan-drug designation for HoFH. Orphan-drug exclusivity generally provides seven years of market exclusivity in the United States from approval, subject to the statutory framework and the continued ability to meet the orphan designation requirements.[2]

Regulatory item	KYNAMRO status
FDA approval date	January 29, 2013
Orphan exclusivity period	Approximately seven years from approval
New chemical entity exclusivity	Likely expired with the original statutory period
Pediatric exclusivity	No established additional six-month period identified in the core product record
Current U.S. approval	Withdrawn at sponsor request
Current commercial marketing	Discontinued

The FDA published withdrawal of approval for KYNAMRO after the sponsor requested withdrawal. The withdrawal was not based on a finding that the drug was withdrawn for reasons of safety or effectiveness under the statutory procedure cited in the notice.[3]

What is the Orange Book status of KYNAMRO?

KYNAMRO was approved under NDA 203568. Its current commercial status is discontinued, and its approval was withdrawn. The Orange Book and Drugs@FDA records should be distinguished:

• The product’s former NDA record remains relevant for regulatory history.
• Discontinued status does not mean the product has an active commercial market.
• Any patent listing must be reviewed against the applicable Orange Book edition and the product’s historical listing status.
• No active generic commercial market has emerged for mipomersen.

The practical implication is that an acquirer cannot assume that historical Orange Book listings create a current market barrier. Patent enforceability, expiration, listing status, and the regulatory pathway for a new application would require separate claim and product analysis.

Are there Paragraph IV challenges or generic-entry risks?

No active, commercially significant Paragraph IV challenge is associated with a marketed U.S. mipomersen generic. The principal near-term risk is therefore not ordinary generic substitution. It is competition from newer lipid-lowering therapies.

A future generic or follow-on applicant could face several issues:

• The reference product is discontinued.
• A 505(j) pathway may be difficult if the reference product is not readily available for required comparative testing.
• The active ingredient is a complex antisense oligonucleotide, which can complicate analytical and pharmaceutical equivalence demonstrations.
• Injectable sterile manufacturing creates additional controls.
• Formulation and device differences could push a developer toward a 505(b)(2) pathway.
• Historical safety findings could affect labeling and development economics.

The absence of a marketed generic does not remove patent or regulatory risk. It shifts the competitive analysis toward reference-product availability, analytical comparability, manufacturing controls, and clinical safety.

Does KYNAMRO face biosimilar risk?

KYNAMRO is not a biologic licensed under the Public Health Service Act and is not a biosimilar reference product. A conventional biosimilar pathway does not apply.

The relevant competitors are:

• Generic or follow-on oligonucleotide products
• 505(b)(2) products with formulation or delivery changes
• PCSK9 inhibitors
• ANGPTL3-targeting therapies
• Other antisense or RNA-based lipid-lowering agents
• Apheresis and specialized HoFH treatments

Inclisiran, evolocumab, and lomitapide occupy different regulatory and technical categories but compete for the same clinical and budgetary decisions in severe lipid disorders. Evinacumab is particularly relevant in HoFH because it has a specific FDA indication for reducing LDL cholesterol in patients aged 12 years and older with HoFH.[4]

How does KYNAMRO compare with competing lipid-lowering products?

Product	Modality	Typical dosing pattern	HoFH relevance	Formulation opportunity
KYNAMRO	Antisense oligonucleotide	Weekly subcutaneous injection	Historical HoFH product	Improve tolerability, device, and dosing burden
Evinacumab	Monoclonal antibody	Intravenous infusion	Direct HoFH competitor	Infusion reduction or subcutaneous delivery
Lomitapide	Small molecule	Oral daily dosing	HoFH treatment	Improve gastrointestinal tolerability and hepatic profile
Evolocumab	Monoclonal antibody	Subcutaneous every two or four weeks	Used in severe hypercholesterolemia	Autoinjector and room-temperature stability
Inclisiran	siRNA	Infrequent subcutaneous administration	Severe LDL-C reduction	Injection-volume and depot-delivery optimization

KYNAMRO’s original competitive weakness was the combination of weekly administration, injection-site reactions, and hepatic monitoring. Any commercial redevelopment would need to address those factors directly.

Which patents and know-how matter for KYNAMRO redevelopment?

The relevant IP categories are broader than patents covering the mipomersen sequence. A commercial diligence review should separate:

1. Composition-of-matter claims covering mipomersen or related oligonucleotide structures.
2. Sequence claims covering apoB-directed antisense compounds.
3. Backbone and sugar-modification claims.
4. Formulation claims covering concentration, pH, tonicity, or stabilizers.
5. Device claims covering prefilled syringes or autoinjectors.
6. Manufacturing claims covering solid-phase synthesis, purification, desalting, and impurity control.
7. Method-of-use claims covering HoFH, LDL reduction, or dosing schedules.
8. Combination claims involving statins, ezetimibe, lomitapide, PCSK9 inhibitors, or apheresis.

For a new developer, manufacturing IP may be more important than a basic sodium chloride formulation. Commercial-scale antisense production requires control of sequence-related impurities, shortmers, n-1 species, oxidation products, residual reagents, counterions, and endotoxin.

What manufacturing barriers exist?

A viable supplier needs:

• GMP oligonucleotide synthesis capacity
• Purification at commercial scale
• Validated sterile filtration and aseptic filling
• High-resolution impurity methods
• Control of residual solvents and reagents
• Reliable sodium-counterion exchange
• Stability-indicating assays
• Prefilled-syringe assembly capability

The manufacturing process can create protectable know-how even where the final excipient composition is simple. A sponsor may obtain more defensible competitive protection through process control, impurity specifications, device integration, and delivery technology than through a basic buffer claim.

What geographic opportunities remain?

The commercial opportunity is geographically concentrated.

Geography	Commercial assessment
United States	Original approval withdrawn; redevelopment would require a new regulatory and commercial strategy
European Union	KYNAMRO was not established as a broadly marketed EU product; EMA experience with mipomersen was unfavorable
Japan	No established major KYNAMRO market
China	HoFH diagnosis and specialty access are developing, but local regulatory and reimbursement requirements are substantial
Middle East and Latin America	Small patient populations and limited access to specialty lipid therapies
Global rare-disease markets	Potential access through named-patient, compassionate-use, or specialty-center channels, subject to local law

The United States remains the clearest regulatory reference point because the product had an FDA approval. The commercial value of other territories would depend on local HoFH diagnosis, reimbursement, genetic testing, lipid-specialist infrastructure, and access to competing therapies.

How strong is the KYNAMRO excipient estate?

The excipient estate appears commercially modest when viewed only as a composition. Sodium chloride, pH adjusters, and water for injection are low-differentiation ingredients. Their value lies in the validated combination with a high-concentration antisense active, the container-closure system, and the manufacturing process.

A stronger redevelopment estate would target:

• A lower-volume formulation
• Reduced injection-site pain
• A specific pH and ionic-strength range
• A stable high-concentration solution
• Autoinjector compatibility
• Extended room-temperature storage
• Reduced syringe adsorption
• Sustained-release or targeted hepatic delivery
• Combination treatment regimens

The strongest claims would need to show a measurable technical effect, such as improved stability, lower aggregation, reduced injection pain, better dose recovery, or improved pharmacokinetics.

What is the commercial outlook for KYNAMRO?

KYNAMRO has limited value as a simple discontinued-product revival. The asset could have strategic value if acquired as part of a broader package containing:

• Rights to mipomersen-related intellectual property
• Clinical and safety data
• Manufacturing documentation
• Analytical methods
• Supplier relationships
• Device development history
• Global regulatory records

A new formulation by itself may not justify development expenditure because the active ingredient’s safety and tolerability history remains central. The commercially credible path is a differentiated product with lower administration burden, better hepatic exposure management, or a delivery platform that improves the risk-benefit profile.

Key Takeaways

• KYNAMRO used a simple injectable excipient system: sodium chloride, pH adjusters, and water for injection.
• The original product was a 100 mg/mL, 2 mL prefilled syringe administered once weekly.
• The U.S. approval was withdrawn after commercial discontinuation.
• No biosimilar pathway applies because KYNAMRO is a synthetic antisense oligonucleotide, not a biologic licensed under the biosimilar framework.
• The main competitive risk comes from newer HoFH and LDL-lowering therapies, not an established mipomersen generic.
• Excipient innovation has value only if it improves injection-site tolerability, stability, concentration, device compatibility, or dosing convenience.
• The strongest commercial opportunity is a reengineered delivery system or combination product, not a minor buffer substitution.
• Manufacturing controls, impurity specifications, device integration, and formulation know-how may provide greater protection than the basic excipient composition.

FAQs

Can KYNAMRO be reformulated with a different buffer?

Yes. A reformulation could evaluate histidine, phosphate, acetate, or citrate systems, but any change would require comparative stability, local-tolerance, device-compatibility, and regulatory studies.

Could a new KYNAMRO formulation receive orphan-drug exclusivity again?

A new product could potentially seek orphan designation if it satisfies current statutory and regulatory requirements. Prior orphan designation for the original product would not automatically confer new exclusivity on a materially different product.

Is KYNAMRO suitable for an autoinjector?

Potentially. The 2 mL dose volume, injection force, viscosity, needle gauge, and syringe compatibility would determine feasibility. A lower-volume or higher-concentration formulation would improve device prospects but could increase viscosity and injection-site pain.

Would a preservative-free multidose KYNAMRO product have commercial value?

It could reduce packaging and administration costs, but it would require strong microbial-control evidence and a suitable multidose device. The regulatory burden would exceed that of the original single-dose presentation.

Which excipient strategy is most likely to create defensible IP?

A formulation that combines high concentration, reduced injection-site pain, extended stability, low adsorption, and compatibility with an autoinjector is more defensible than a routine substitution of sodium chloride or a pH adjuster.

References

1. U.S. Food and Drug Administration. (2013). KYNAMRO (mipomersen sodium) injection prescribing information.
2. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity.
3. U.S. Food and Drug Administration. (2019). Withdrawal of approval of new drug application for KYNAMRO. Federal Register.
4. U.S. Food and Drug Administration. (2021). EVKEEZA (evinacumab-dgnb) injection prescribing information.
5. European Medicines Agency. (2013). Kynamro: Questions and answers on refusal of marketing authorisation.